Objectives This study aimed to provide a systematic review of device‐associated thrombosis
(DAT) after left atrial appendage occlusion (LAAO) with the Watchman, Amplatzer Cardiac …

Percutaneous left atrial appendage (LAA) exclusion is an evolving treatment to prevent
embolic events in patients with nonvalvular atrial fibrillation. In the past few years multiple …

Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia. The
estimated prevalence in the general population is 1–2% and increases with age. 1–8 …

BACKGROUND Suicide is a leading cause of preventable death worldwide, with its peak of
maximum incidence in later life. Depression often puts an individual at higher risk for …

The left atrial appendage (LAA) is a complex and heterogeneous protruding structure of the
left atrium (LA). In atrial fibrillation patients, it is the location where 90% of the thrombi are …

Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia. The
estimated prevalence in the general population is 1-2% and increases with age. 1-8 Patients …

Background Transcatheter left atrial appendage (LAA) occlusion has been proven to be an
effective treatment for stroke prophylaxis in patients with atrial fibrillation. For this purpose …

Objectives: This study sought to define the ideal post-procedural anticoagulant regime and
to systematically study the incidence of device-related thrombus. Background: Left atrial …

Abstract Background The Amplatzer™ Amulet™(Amulet) is the evolution of the Amplatzer™
Cardiac Plug, a dedicated device for percutaneous left atrial appendage (LAA) occlusion …

Left atrial appendage (LAA) occlusion devices have the potential to influence the clinical
approach to stroke prevention in patients with atrial fibrillation (AF). A number of …